Clin Cancer Research: Autophagy inhibitor hydroxychloroquine combined with gisitabin/nab yew alcohol as a preoperative treatment for pancreatic cancer

BACKGROUND: Herbert JZeh et alspeculated that autophagy inhibition or enhanced response to chemotherapy in patients withpancreatic cancer, and conducted a randomized controlled trial to evaluate the efficacy of autophagy inhibitors hydroxychloroquine in combination with gixitamin and nab eucalyptusmethod: recruit edipable pancreatic cancer patients, randomly assigned to the Gixithabin-Nabe yew alcohol (PG) group or Gisitabin-Nabu yewol and hydroxychloroquinol (PGH), followed by surgical removalThe main endpoint is the organized pathological reaction of surgical excision tissueSecondary clinical endpoints include serum CA19-9 and cut-back negative R0 excisionresults: 34 patients in the PGH and 30 patients in the PG group were able to perform primary endpoint assessmentsCompared to the PG group, the Decline graded tissue pathology remission in the PGH group was significantly improved (p.00016)In patients with elevated CA199, CA199 drops to normal and is associated with improved overall survival rate and no recurrence survival time (p 0.0001)There were significant differences in the severe adverse reactions between the two treatment groups, and the number of chemotherapy doses was comparableThere was higher evidence of autophagy inhibition in the PGH group excision samples (SQSTM1 elevated, p-0.027,immunecell tumor immersion also increased, p-0.033), but no significant difference in recurrence survivalconclusion: In the preoperative gisitabin-nab yew alcohol chemotherapy program, the addition of hydroxychloroquine can improve pathological tumor remission, improve serum biomarker remission (CA199), and enhance autophagy inhibition and immune activity